VEEVA SYSTEMS INC Q3 FY2026 earnings

The migration of Veeva CRM customers from the Salesforce platform to Vault CRM is complex and may cause disruptions or customer losses; Salesforce's agreement expired September 1, 2025, and the wind-down through September 1, 2030 restricts new sales and seat expansion. Salesforce has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions.

Veeva AI, which will add AI across clinical, regulatory, safety, quality, medical, and commercial applications, creates risks of reputational harm, regulatory scrutiny, and liability if outputs are inaccurate or biased. Evolving AI regulations such as the EU AI Act may require significant changes to the company's AI use and increase compliance costs.

The markets are highly competitive, and Salesforce, which has developed a life sciences CRM and licensed IQVIA's CRM software, is the primary CRM competitor. Competitors have greater resources and have offered price concessions or delayed payment terms in the recent macroeconomic environment, which could pressure Veeva's revenues and margins.

The top 10 customers accounted for 28% of total revenues in the fiscal year ended January 31, 2025, and the loss or non-renewal of one or more key customers could slow revenue growth. Increasing purchasing scrutiny at renewal for large customers may result in reductions in user subscriptions or pricing pressure.

Nearly all revenues come from life sciences customers, so demand is exposed to drug pricing reforms such as the Inflation Reduction Act and proposals by the current administration, government funding and staffing changes at agencies like the FDA, NIH, and Medicaid, industry consolidation, and reductions in life sciences sales representatives.

Increasingly complex privacy, data protection, and cybersecurity rules affect Veeva's products. The EU Data Act, effective September 12, 2025, allows EU customers to cancel subscriptions without cause, China data transfer approvals were denied for certain Veeva CRM customers, and Washington's My Health My Data Act led to modifications to Veeva Crossix audience segments that may reduce demand.

Veeva relies on Amazon Web Services and Salesforce for computing infrastructure, and any disruption, capacity issue, or failure by these providers could interrupt services and harm customer relationships. The Salesforce platform agreement expired September 1, 2025, and if availability ends earlier than anticipated, Veeva CRM operations would be adversely affected.

Veeva processes sensitive customer, patient, and clinical trial data, and breaches or unauthorized access could cause liability, regulatory investigations, reputational damage, and loss of customers. Geopolitical tensions and AI-enabled attack methods may elevate the risk of sophisticated cyberattacks.

Most subscription orders have one-year terms and customers have no obligation to renew; failure to renew, renew at lower levels, or early termination would hurt revenues. The EU Data Act also lets EU customers cancel subscriptions without cause after a transition period, and larger customers increasingly negotiate pricing at renewal.

Sales cycles can span 12 months or longer and are difficult to predict, and Veeva has recently experienced increased scrutiny for certain potential projects, particularly professional services offerings, which may continue. Lengthening sales cycles or unsuccessful pursuit of opportunities would harm operating results and growth.

Veeva faces intense competition for highly skilled employees and expects continued difficulty hiring and retaining them; the perceived value of equity awards can decline with stock price drops, impairing recruitment and retention. Newly hired sales professionals may take six to nine months or longer to become productive.

Professional services revenues and gross margin are volatile and may not increase quarter to quarter; the professional services gross margin decreased in the quarter ended October 31, 2025 compared with the prior-year quarter, which management attributes to headcount expansion. This could pressure overall profitability if services demand or utilization weakens.

Uncertain macroeconomic and geopolitical factors, including tariffs, inflation, currency fluctuations, interest-rate changes, conflicts in Ukraine and the Middle East, and recession concerns, could cause instability and reduce life sciences IT spending. International customers outside North America were about 41% of total revenues in the fiscal year ended January 31, 2025, and currency changes negatively affected revenues in FY2025 and FY2024 and may do so again in FY2026.

The effective tax rate increased for both the quarter and nine months ended October 31, 2025 compared with the prior-year periods, primarily due to indirect effects of the One Big Beautiful Bill Act. Global tax reforms such as Pillar Two and tax audits could further increase the effective tax rate.